Scientists develop new treatment for pain associated with sciatica and migraines

Scientists develop new treatment for pain associated with sciatica and migraines

Neurolieve Biosciences, a biotech company backed by NLC Health Ventures, is developing a new treatment aimed at improving the lives of those suffering from neuropathic pain. 

Neuropathic pain is a condition that affects tens of millions around the world. There are many different causes but each is underpinned by damage to the nervous system, leading to profound, long-term, debilitating discomfort and a decrease in quality of life. Severe physical and psychological consequences are sadly uniting features. This type of pain is notoriously difficult to manage, with current medications being either poorly effective and/or carrying equally harmful side effects. For those affected, everyday tasks become challenging and the impact of neuropathic pain is profound, imposing a heavy economic and social burden. 

Neurolieve Biosciences is developing an innovative, bioengineered protein-based therapy designed to target the root causes of neuropathic pain. This novel treatment works by specifically interacting with nerve cells of pain-sensing systems to decrease pain sensitivity, yet without the common side effects of current medications. 

The therapy, which has been exclusively licensed to Neurolieve by LifeArc, was developed by its scientists at its drug discovery laboratories following a collaboration with Professor David Wynick at the University of Bristol.

“Our mission at Neurolieve Biosciences is to bring forth solutions that significantly enhance the quality of life for those afflicted by neuropathic pain. By focusing on the underlying processes that trigger neuropathic pain, our treatment represents a significant advancement in pain management, offering a promising new option for patients seeking relief from the debilitating effects of neuropathic pain,” said Massimo Mineo, CEO of Neurolieve Biosciences.

Jeff Jerman, Head of Translational Matrix at LifeArc adds, “This innovative approach has great potential to positively impact the lives of a currently underserved group of patients. It has been a privilege to be part of this collaborative team effort, which has delivered intellectual and practical innovation that has allowed us to move the idea from inception to reality. It is so rewarding to see this drug solution moving into the next phase of clinical development.”

With a vision to be at the forefront of innovation in treating neuropathic pain, Neurolieve Biosciences is setting new standards in the field. Neurolieve Biosciences' pioneering work offers hope to millions suffering from neuropathic pain.